NCT03214991 is a clinical trial in Pancreatic Cancer, sponsored by Ji Kon Ryu.

Who is sponsoring NCT03214991?

NCT03214991 is sponsored by Ji Kon Ryu.

What condition does NCT03214991 study?

NCT03214991 studies Pancreatic Cancer.

Is NCT03214991 still recruiting?

NCT03214991 is currently status unknown. Last updated 5 February 2018.

Last reviewed 2018-02-05 · How we verify

NCT03214991

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer

Status unknown Last updated 5 February 2018

What this trial tests

trial in Pancreatic Cancer in 100 participants. Status unknown.

Timeline

12 May 2017

Primary endpoint
30 September 2020

31 March 2021

Quick facts

Lead sponsor	Ji Kon Ryu
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	12 May 2017
Primary completion	30 September 2020
Estimated completion	31 March 2021
Sites	1 location across South Korea

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Ji Kon Ryu

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine the usefulness of circulating tumor DNA as a prognostic factor in patients with pancreatic cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues.
Wu X, Zhu L, Ma PC. · · 2018 · cited 17× · PMID 30231325 · DOI 10.1200/edbk_199767
Diagnostic biomarkers for pancreatic cancer: An update.
Yang M, Zhang CY. · · 2021 · cited 14× · PMID 34963749 · DOI 10.3748/wjg.v27.i45.7862

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Ji Kon Ryu trials

Trials by the same sponsor.

NCT03718897 — Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03214991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ji Kon Ryu
Last refreshed: 5 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03214991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing